ALT Altimmune Inc

Altimmune to Present at Upcoming Virtual Investor Conferences

Altimmune to Present at Upcoming Virtual Investor Conferences

GAITHERSBURG, Md., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company advancing proprietary intranasal vaccines and peptide therapeutics for liver disease, today announced that management will present at the following upcoming virtual investor conferences:

Jefferies London Virtual Healthcare Conference

Tuesday, November 17, 2020

11:25 am Eastern Time

Piper Sandler 32nd Annual Virtual Healthcare Conference

Monday, November 23, 2020 to Thursday, December 3, 2020

Fireside chat recording available to conference participants

3rd Annual Evercore ISI Virtual HealthCONx Conference

Wednesday, December 2, 2020

8:00 am Eastern Time

The sessions will be webcast and can be accessed by visiting the investor relations section of the company's website at under Events / Presentations.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. The Company’s diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell). For more information on Altimmune, please visit .

Investor Contacts:

   
Stacey Jurchison

Altimmune, Investor Relations

Phone: 410-474-8200

 Ashley R. Robinson

LifeSci Advisors, LLC

617-430-7577

 


EN
16/11/2020

Underlying

ALTAltimmune Inc

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Altimmune Inc

 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD...

Altimmune Appoints Industry Veteran Christophe Arbet-Engels, M.D., PhD as Chief Medical Officer to Drive Next Phase of Clinical Development of Pemvidutide  Seasoned clinical leader to oversee Phase 3 development of pemvidutide in MASH Dr. Arbet-Engels has led late-stage development, regulatory approvals and commercial launches for multiple successful franchises GAITHERSBURG, Md., Sept. 29, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appoint...

September 29, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate in Two Upcoming Investor Conferences

Altimmune to Participate in Two Upcoming Investor Conferences GAITHERSBURG, Md., Sept. 23, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced that members of the Company’s management team will participate and be available for 1x1 meetings at the following investor conferences: Stifel 2025 Virtual Cardiometabolic ForumTuesday, September 30, 2025Fireside Chat at 10:30 a.m. Eastern Time H.C. Wainwright Liver Disease Virtual ConferenceTuesday, October 21,...

September 23, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Appoints Accomplished Commercial Executive Linda M. Richards...

Altimmune Appoints Accomplished Commercial Executive Linda M. Richardson as Chief Commercial Officer GAITHERSBURG, Md., Sept. 15, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing novel peptide-based therapeutics for liver and cardiometabolic diseases, today announced the appointment of Linda M. Richardson to the role of Chief Commercial Officer, effective September 16, 2025. Ms. Richardson joins the Company with more than 30 years of experience in sales and marketing, commercial, corporate and business development across a range of therap...

September 15, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune to Participate in Upcoming Investor Conferences

Altimmune to Participate in Upcoming Investor Conferences GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences: Wells Fargo Healthcare Conference in Boston, MA Friday, September 5, 2025 One-on-one meetings only H.C. Wainwright Global Investment Conference in New York, NY Tuesday, September 9, 2025 Fireside chat at 8:30 a....

August 26, 2025 1 EN
 PRESS RELEASE
Free
ALT ALTIMMUNE INC

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alco...

Altimmune Announces FDA Fast Track Designation for Pemvidutide in Alcohol Use Disorder (AUD) Pemvidutide is the only drug currently granted Fast Track Designation in AUD RECLAIM, a Phase 2 trial of pemvidutide in AUD, is currently enrolling GAITHERSBURG, Md., Aug. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to pemvidutide for the treatment of Alcohol Use Disorder ...

August 19, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch